Thrombotargets in collaboration with Intelligent Pharma was awarded with the grant Technological innovation Nuclis 2014, given by the Generalitat de Catalunya. The project titled "Development of new inhibitors of the protrombinase complex" has developed small molecules with anticoagulant properties, combining molecular modelling techniques and phenotypic assays. The collaboration has rendered innovative anticoagulant hits, and has allowed the design and creation of chemoinformatics analysis for the establishment of mechanisms of action of phenotypic observations. These new hits are being developed so that they can be out-licensed or co-developed with a mid-sized/big pharma or biotech company.
Thrombotargets receives funding for two new research projects, in cancer and angiogenesis, from the Ministry of Economy, Industry and Competitiveness and co-financed through FEDER funds of the EUROPEAN UNION
Find us at:
BioEuropeSpring 2017, Barcelona, March 20th to 22nd
BioKorea 2017, Seoul, April 12th to 14th
BIO2017, San Diego, June 19th to 22nd